biostudies-literatureFernandez-Martos CNational Institute for Health Research (NIHR)1042-3https://www.ebi.ac.uk/biostudies/studies/S-EPMC4201001biostudies-literatureUnknown19(10)<h4>Background</h4>The need for preoperative chemoradiation or short-course radiation in all T3 rectal tumors is a controversial issue. A multicenter phase II trial was undertaken to evaluate the efficacy and safety of neoadjuvant capecitabine and oxaliplatin combined with bevacizumab in patients with intermediate-risk rectal adenocarcinoma.<h4>Methods</h4>We recruited 46 patients with T3 rectal adenocarcinoma selected by magnetic resonance imaging (MRI) who were candidates for (R0) resection located in the middle third with clear mesorectal fascia and who were selected by pelvic MRI. Patients received four cycles of neoadjuvant capecitabine and oxaliplatin combined with bevacizumab (final cycle without bevacizumab) before total mesorectal excision (TME). In case of progression, preoperatiThe oncologistPreoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial.PMC4201001NF-SI-0507-10161Serra JGallego JEstevan RAlonso VBrown GSafont MJSantos JDelgado SFernandez-Martos CRoig JVMontagut CMaurel JFeliu JSierra EAparicio JVera RPera MMartin MSalud APericay CfalsePreoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial.<h4>Background</h4>The need for preoperative chemoradiation or short-course radiation in all T3 rectal tumors is a controversial issue. A multicenter phase II trial was undertaken to evaluate the efficacy and safety of neoadjuvant capecitabine and oxaliplatin combined with bevacizumab in patients with intermediate-risk rectal adenocarcinoma.<h4>Methods</h4>We recruited 46 patients with T3 rectal adenocarcinoma selected by magnetic resonance imaging (MRI) who were candidates for (R0) resection located in the middle third with clear mesorectal fascia and who were selected by pelvic MRI. Patients received four cycles of neoadjuvant capecitabine and oxaliplatin combined with bevacizumab (final cycle without bevacizumab) before total mesorectal excision (TME). In case of progression, preoperati2014-01-01T00:00:00Z2014 Oct2026-05-04T20:51:36.792Z2019-03-27T01:37:54ZS-EPMC42010012520937610.1634/theoncologist.2014-0233